^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    MB-105

    i
    Other names: MB-105, MB-105 PSCA CAR, PSCA(dCH2)BBzeta-CAR T-cell, MB105
    Associations

    News

    Trials
    Company:
    Fortress
    Drug class:
    PSCA-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    16d
    PSCA-Targeting CAR-T Cells Plus or Minus Radiation for the Treatment of Patients With PSCA+ Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov)
    P1, N=21, Recruiting, City of Hope Medical Center | Trial completion date: Nov 2026 --> Nov 2028 | Trial primary completion date: Nov 2026 --> Nov 2028
    Trial completion date • Trial primary completion date
    |
    PSCA (Prostate Stem Cell Antigen 2)
    |
    MB-105
    3ms
    Comparative efficacy and safety of PSCA CAR-engineered Vδ1 γδ T cells for immunotherapy of pancreatic cancer. (PubMed, J Immunother Cancer)
    PSCA CAR-Vδ1 γδ T cells represent a potent and safe therapeutic modality for PSCA+ PC, with efficacy comparable to other CAR T cell types and potential advantages in safety and persistence. These findings support further development of CAR-Vδ1 T cell immunotherapy for solid tumors.
    Clinical • Journal
    |
    PSCA (Prostate Stem Cell Antigen 2)
    |
    MB-105
    5ms
    PSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov)
    P1, N=14, Active, not recruiting, City of Hope Medical Center | Trial completion date: May 2025 --> Apr 2026
    Trial completion date
    |
    PSCA (Prostate Stem Cell Antigen 2)
    |
    cyclophosphamide • fludarabine IV • MB-105
    8ms
    Off-the-shelf invariant NKT cells expressing anti-PSCA CAR and IL-15 promote pancreatic cancer regression in mice. (PubMed, J Clin Invest)
    In multiple in vitro and in vivo PDAC models, freshly manufactured PSCA CAR_sIL-15 iNKT cells and frozen-thawed, off-the-shelf PSCA CAR_sIL-15 iNKT cells demonstrate comparable efficacies, and both show remarkable suppression of PSCA-positive and gemcitabine-resistant PDAC. Importantly, off-the-shelf cryopreserved PSCA CAR_sIL-15 iNKT cells show equivalent efficacy when compared with PSCA CAR T cells using the same PSCA CAR and in the same PDAC model; however, PSCA CAR_sIL-15 iNKT cells do not appear to induce systemic toxicity or graft-versus-host disease, thus allowing for multiple infusions to control recurrent disease. Collectively, our study suggests that PSCA CAR_sIL-15 iNKT cells merit clinical investigation for PDAC patients exhibiting positive PSCA expression. The therapy could be given as a single agent or in combination with established therapeutic modalities for PDAC.
    Preclinical • Journal
    |
    IL15 (Interleukin 15) • PSCA (Prostate Stem Cell Antigen 2)
    |
    gemcitabine • MB-105
    8ms
    PSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov)
    P1, N=14, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2024 --> May 2025
    Trial completion date
    |
    PSCA (Prostate Stem Cell Antigen 2)
    |
    cyclophosphamide • fludarabine IV • MB-105
    1year
    PSCA-Targeting CAR-T Cells Plus or Minus Radiation for the Treatment of Patients With PSCA+ Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov)
    P1, N=21, Recruiting, City of Hope Medical Center | Trial completion date: Jul 2028 --> Nov 2026 | Trial primary completion date: Aug 2027 --> Nov 2026
    Trial completion date • Trial primary completion date • CAR T-Cell Therapy • Metastases
    |
    PSCA (Prostate Stem Cell Antigen 2)
    |
    PSCA Expression
    |
    MB-105
    over1year
    PSCA-CAR T cell therapy in metastatic castration-resistant prostate cancer: a phase 1 trial. (PubMed, Nat Med)
    These results support future clinical studies to optimize dosing and combination strategies to improve durable therapeutic outcomes. ClinicalTrials.gov identifier NCT03873805 .
    P1 data • Journal • CAR T-Cell Therapy • Metastases
    |
    PSCA (Prostate Stem Cell Antigen 2)
    |
    MB-105
    over1year
    PSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov)
    P1, N=14, Active, not recruiting, City of Hope Medical Center | Trial completion date: Mar 2024 --> Dec 2024
    Trial completion date • CAR T-Cell Therapy • Metastases
    |
    PSCA (Prostate Stem Cell Antigen 2)
    |
    cyclophosphamide • fludarabine IV • MB-105
    over1year
    Human anti-PSCA CAR macrophages possess potent antitumor activity against pancreatic cancer. (PubMed, Cell Stem Cell)
    We optimized the cryopreservation of CAR-iMac progenitors that remain functional upon thawing, providing an off-the-shelf, allogeneic cell product that can be developed into CAR-iMacs. Overall, our preclinical data strongly support the potential clinical translation of this human iPSC-derived platform for solid tumors, including pancreatic cancer.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • PSCA (Prostate Stem Cell Antigen 2)
    |
    MB-105
    over1year
    PSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov)
    P1, N=14, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2023 --> Mar 2024
    Trial completion date • CAR T-Cell Therapy • Metastases
    |
    PSCA (Prostate Stem Cell Antigen 2)
    |
    cyclophosphamide • fludarabine IV • MB-105
    almost2years
    PSCA-Targeting CAR-T Cells Plus or Minus Radiation for the Treatment of Patients With PSCA+ Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov)
    P1, N=21, Recruiting, City of Hope Medical Center | Trial completion date: Nov 2025 --> Jul 2028 | Trial primary completion date: Nov 2025 --> Aug 2027
    Trial completion date • Trial primary completion date • CAR T-Cell Therapy • Metastases
    |
    PSCA (Prostate Stem Cell Antigen 2)
    |
    PSCA Expression
    |
    MB-105
    almost2years
    PSCA-Targeting CAR-T Cells Plus or Minus Radiation for the Treatment of Patients With PSCA+ Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov)
    P1, N=21, Recruiting, City of Hope Medical Center | Phase classification: P1b --> P1 | Trial completion date: Feb 2026 --> Nov 2025 | Trial primary completion date: Feb 2026 --> Nov 2025
    Phase classification • Trial completion date • Trial primary completion date • CAR T-Cell Therapy • Metastases
    |
    PSCA (Prostate Stem Cell Antigen 2)
    |
    PSCA Expression
    |
    MB-105